National Drug Control Strategy

National Drug Control Strategy
Name	National Drug Control Strategy
Publisher	Executive Office of the President
Date	Annual
Country	United States
Subject	Drug policy

National Drug Control Strategy

The National Drug Control Strategy is an annual policy document produced by the Executive Office of the President that articulates priorities for coordinating federal responses to substance use, aligning agencies such as the White House, Department of Health and Human Services, Department of Justice, Department of Homeland Security, Department of Defense, Department of Education, Department of Labor, Department of Veterans Affairs, Department of Housing and Urban Development, Department of Transportation, Department of Treasury, and the Office of National Drug Control Policy. The Strategy situates U.S. efforts alongside international counterparts including the United Nations Office on Drugs and Crime, the World Health Organization, the Organization of American States, the European Monitoring Centre for Drugs and Drug Addiction, and partner governments such as Canada, Mexico, Colombia, Brazil, the United Kingdom, France, Germany, Australia, India, China, and Japan.

Overview

The Strategy synthesizes input from a constellation of institutions and events such as the White House National Security Council, Cabinet-level meetings, the Drug Enforcement Administration, the Federal Bureau of Investigation, the Central Intelligence Agency, the Joint Chiefs of Staff, the Congressional committees like the Senate Committee on Homeland Security and Governmental Affairs and the House Committee on Energy and Commerce, and hearings involving figures referenced in legislation such as the Controlled Substances Act, the Anti-Drug Abuse Act, the Comprehensive Addiction and Recovery Act, the SUPPORT for Patients and Communities Act, and key administrations dating back to Nixon, Reagan, Clinton, Bush, Obama, Trump, and Biden. It frames its approach through empirical contributions from scholars associated with institutions such as Harvard University, Johns Hopkins University, Yale University, Columbia University, Stanford University, the University of California system, and nonprofit organizations including the Robert Wood Johnson Foundation, the Pew Charitable Trusts, RAND Corporation, Brookings Institution, Kaiser Family Foundation, and the Cato Institute.

Objectives and Priorities

The Strategy sets priorities that reflect public debates exemplified in events and movements associated with the War on Drugs, the opioid epidemic, the crack cocaine crisis, the methamphetamine surge, and the fentanyl proliferation tied to transnational criminal organizations and cartels like the Sinaloa Cartel, the Jalisco New Generation Cartel, and trafficking routes through the U.S.–Mexico border and Caribbean corridors. It enumerates aims aligned with presidential initiatives, bipartisan congressional proposals, advocacy from organizations such as the American Medical Association, the American Psychiatric Association, the American Bar Association, the National Association of Counties, the National League of Cities, and state-level offices including the California Department of Public Health, the New York State Department of Health, the Massachusetts Department of Public Health, and the Ohio Department of Mental Health and Addiction Services.

Policy and Legal Framework

The document references statutes and legal frameworks including the Controlled Substances Act, the Harrison Narcotics Tax Act, the Marihuana Tax Act, the Anti-Drug Abuse Act, the Comprehensive Crime Control Act, the Illicit Drug Anti-Proliferation Act, the SUPPORT Act, state ballot measures such as Proposition 215 and initiatives in Colorado and Washington, and Supreme Court decisions that shape enforcement and civil liberties considerations. It interacts with agencies and treaties like the Drug Enforcement Administration, Customs and Border Protection, Immigration and Customs Enforcement, the Department of State’s Bureau of International Narcotics and Law Enforcement Affairs, the United Nations Single Convention on Narcotic Drugs, the Geneva Conventions, and regional accords brokered via the Organization of American States.

Prevention and Public Health Initiatives

Prevention strategies draw on public health research from institutions and campaigns associated with the Centers for Disease Control and Prevention, the National Institutes of Health, the Substance Abuse and Mental Health Services Administration, the Food and Drug Administration, the Surgeon General, and programs modeled on historical efforts such as D.A.R.E., community coalitions like those supported by the Community Anti-Drug Coalitions of America, school-based efforts linked to the Department of Education, workforce initiatives with the Department of Labor, and faith-based and tribal programs involving the Bureau of Indian Affairs. The Strategy cites partnerships with local health departments, primary care networks, academic medical centers including Massachusetts General Hospital, Johns Hopkins Hospital, and UCLA Health, and international public health actors such as WHO and PAHO.

Law Enforcement and Supply Reduction

Supply reduction components coordinate actions by the Drug Enforcement Administration, Federal Bureau of Investigation, Bureau of Alcohol, Tobacco, Firearms and Explosives, Immigration and Customs Enforcement, U.S. Coast Guard, National Guard units, Europol, Interpol, and partner nation security forces. Operations referenced include interdiction campaigns, international investigations targeting cartels and transnational criminal organizations, initiatives to secure ports of entry and postal systems, financial enforcement actions involving the Financial Crimes Enforcement Network, sanctions administered via the U.S. Department of the Treasury, and prosecutions pursued by U.S. Attorneys’ Offices and trials in District Courts and the U.S. Court of Appeals.

Treatment, Recovery, and Harm Reduction

Treatment and recovery strategies emphasize evidence-based modalities such as medication-assisted treatment, programs modeled after the Massachusetts Model, the Portland clinic networks, peer recovery supports like those advanced by Faces & Voices of Recovery, and harm reduction measures promoted by syringe service programs, naloxone distribution campaigns, supervised consumption site debates involving municipal governments, and criminal justice diversion programs like drug courts, reentry initiatives, Veterans Affairs treatment programs, and Medicaid expansion under the Affordable Care Act. Collaboration includes stakeholders such as the American Society of Addiction Medicine, National Institutes of Health research centers, the Robert Wood Johnson Foundation, state Medicaid agencies, and municipal public health departments.

Evaluation, Data, and Funding

Evaluation relies on surveillance systems and data collection administered by the Centers for Disease Control and Prevention’s National Vital Statistics System, the National Survey on Drug Use and Health, Drug Enforcement Administration seizure databases, National Institute on Drug Abuse research, and cross-agency dashboards maintained by the Office of National Drug Control Policy. Funding streams involve appropriations by the United States Congress, allocations to agencies including SAMHSA, NIH, DEA, DOJ, DHS, and grant programs distributed through entities such as the Office of Justice Programs, Health Resources and Services Administration, and state substance abuse agencies. Independent analyses appear from research organizations and think tanks including RAND Corporation, Brookings Institution, Urban Institute, Pew Charitable Trusts, and academic centers that evaluate outcomes, cost-effectiveness, and impacts on public safety, public health, and communities affected by substance use.

Category:United States federal policy